Leqvio (Inclisiran) Cost in Michigan 2026

What Is Inclisiran and Why Does the Price Matter in Michigan?

Inclisiran (brand name Leqvio) is a small-interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA inside hepatocytes, reducing PCSK9 protein production and allowing LDL receptors to recycle more efficiently. The net effect is a sustained reduction in LDL-C of approximately 50% from baseline. Because the molecule acts upstream of PCSK9 protein secretion rather than blocking the circulating protein like a monoclonal antibody, a single subcutaneous dose suppresses LDL-C for roughly six months.

The FDA approved inclisiran in December 2021 for adults with ASCVD or HeFH as an adjunct to maximally tolerated statin therapy. [1] The approval was anchored to the ORION-10 and ORION-11 phase 3 trials published in the New England Journal of Medicine. In ORION-10 (N=1,561), inclisiran 284 mg produced a placebo-adjusted LDL-C reduction of 52.3% at day 510, with an injection-site reaction rate of 2.6% versus 0.9% placebo (P<0.001). [2] ORION-11 (N=1,617) showed a comparable placebo-adjusted reduction of 49.9% at day 510 (P<0.001). [2]

Michigan has roughly 10 million residents and a cardiovascular disease burden above the national median. The American Heart Association estimates that approximately 18.6 million U.S. adults have clinical ASCVD, [3] and Michigan's age-adjusted cardiovascular mortality rate consistently exceeds the national average. [4] For any Michigan patient whose LDL-C remains above guideline targets despite maximally tolerated statins, cost is often the single largest access barrier to inclisiran.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol specifies that PCSK9-targeting therapies should be considered for patients with ASCVD whose LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe. [5] Inclisiran now sits in that same treatment tier, making its price in Michigan a clinically relevant question for a large patient population.

Leqvio List Price vs. Real-World Cost in Michigan in 2026

The Novartis wholesale acquisition cost (WAC) for Leqvio is approximately $3,250 per single-dose syringe. Patients receive two syringes in year one (day 1 and day 90 for loading, then every six months), translating to a WAC of roughly $9 to 750 in year one and $6 to 500 in subsequent years. Divided across 12 months, that is the figure commonly cited as ~$540/month.

Very few cash-pay patients in Michigan actually pay that number. The Novartis Leqvio savings program (discussed in detail below) brings commercially insured patients to $0 or near-$0 per injection. [6] Uninsured Michigan patients without savings card eligibility face the full WAC, which makes exploring compounded alternatives or Medicaid enrollment financially urgent.

Michigan pharmacists note that retail dispensing of Leqvio at cash price is uncommon because the drug is typically administered in a physician's office under a buy-and-bill or specialty pharmacy model rather than a retail counter. Patients should confirm with their prescribing cardiologist or telehealth provider exactly how the drug will be billed, because the site-of-care affects both insurance processing and out-of-pocket exposure. [7]

A practical cost-tier framework for Michigan patients in 2026:

1. Commercially insured (employer or ACA plan) with savings card: $0 per injection is achievable for most patients. Eligibility requires that the plan covers Leqvio on any tier.
2. Michigan Medicaid (Healthy Michigan Plan or traditional Medicaid): Covered with prior authorization; patient cost share is $0 to $3 per drug event under Michigan's Medicaid co-pay schedule.
3. Medicare Part D: Savings cards cannot be applied to federal program claims per CMS rules; [8] patients may owe standard Part D cost-sharing until deductible is met. The Inflation Reduction Act $2,000 out-of-pocket cap takes effect for 2025 and beyond, which may limit total annual exposure.
4. Uninsured or ineligible for savings card: Cash WAC of ~$3,250 per injection. Compounded inclisiran from a licensed Michigan 503A pharmacy represents the most affordable alternative in this tier.

Michigan Medicaid Coverage for Leqvio

Michigan Medicaid covers inclisiran (Leqvio) with prior authorization (PA). The PA criteria align with the drug's FDA-approved indications: clinical ASCVD or HeFH in adults already on maximally tolerated statin therapy. Prescribers must document LDL-C levels, current lipid-lowering regimen, and the reason a less expensive agent (ezetimibe, bile acid sequestrant) is inadequate or has been tried.

Michigan's Medicaid pharmacy benefit is administered through the Michigan Department of Health and Human Services (MDHHS). The preferred drug list (PDL) is updated quarterly; as of 2026, Leqvio sits in the non-preferred specialty tier requiring PA. [9] The PA process typically takes 3 to 5 business days when documentation is complete.

The ACC/AHA Guideline on Non-Statin Therapies for LDL-Cholesterol Lowering explicitly states: "PCSK9 inhibitors are recommended for patients with clinical ASCVD or HeFH who require additional LDL-C lowering beyond maximally tolerated statin therapy." [5] This guideline language provides the clinical rationale PA reviewers typically accept.

Michigan Medicaid members enrolled in Healthy Michigan managed care plans (Meridian, Molina, Blue Cross Complete, etc.) may face plan-specific PA forms in addition to the state PDL requirement. Telehealth providers coordinating Leqvio for Michigan Medicaid patients should submit PA requests through the member's managed care plan, not directly through MDHHS fee-for-service pathways, unless the member is in traditional fee-for-service Medicaid.

Patients who are denied PA have the right to appeal under Michigan's Medicaid grievance and appeals process, and the prescriber may request a peer-to-peer review with the plan's medical director within 10 business days of the denial notice. [10]

Is Compounded Inclisiran Legal in Michigan?

Compounded inclisiran is legal in Michigan when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare drug products for individual patients when a licensed practitioner provides a prescription and the formulation meets USP standards. [11]

Inclisiran is not currently on the FDA's 503B outsourcing facility bulk drug substance list, meaning large-scale 503B compounding of inclisiran for office use (the model used for semaglutide during the shortage) is not authorized at the federal level. The 503A individual-prescription pathway remains intact. Michigan Board of Pharmacy rules require that 503A pharmacies compound only for identified individual patients and cannot produce large batches for speculative distribution. [12]

Practical cost data from Michigan 503A pharmacies show compounded inclisiran priced at significantly less than the Novartis WAC, with some pharmacies offering the drug at a small fraction of the brand cost depending on raw material sourcing. Patients considering this route should confirm with the pharmacy that their bulk active pharmaceutical ingredient (API) is sourced from an FDA-registered supplier and that the formulation has undergone potency and sterility testing. A prescribing clinician at a telehealth platform can support the prescription, but the patient assumes responsibility for verifying pharmacy credentials.

One clinical consideration: compounded inclisiran formulations have not been tested in the key trials used to establish dosing, efficacy, and safety of the Novartis product. The ORION-10 and ORION-11 data apply specifically to the approved 284 mg/1.5 mL subcutaneous formulation. [2] Patients and prescribers should weigh this uncertainty against the cost difference.

Telehealth Prescribing of Leqvio in Michigan

Michigan permits telehealth prescribing of Leqvio by a licensed Michigan physician or advanced practice provider (APP) who has established a valid patient-physician relationship through a synchronous audio-visual encounter. [13] The Michigan Public Health Code and the state telehealth law (PA 375 of 2016 as amended) do not restrict which drug categories can be prescribed via telehealth, provided the prescriber performs an appropriate clinical evaluation.

The practical workflow for telehealth-initiated inclisiran in Michigan typically looks like this. A patient consults with a telehealth cardiologist or internal medicine physician. The clinician reviews recent lipid panels, current medications, and cardiovascular history. If inclisiran is appropriate, the prescription is sent either to a specialty pharmacy for buy-and-bill or to a local infusion clinic, or to a 503A compounding pharmacy for a compounded preparation. The patient then receives the injection at a local clinic, primary care office, or cardiology practice that can bill for the administration.

Telehealth platforms that specialize in lipid management, including HealthRX, can coordinate the full workflow including PA submission, savings card enrollment, and injection site referral.

The Novartis Leqvio Savings Card in Michigan

Novartis operates a patient assistance and copay savings program for Leqvio branded as the "Leqvio Support Program." Commercially insured Michigan patients who meet eligibility criteria may pay $0 per injection. [6] Medicare and Medicaid patients are not eligible for manufacturer savings cards under federal anti-kickback statutes. [8]

Eligibility requirements as of 2026 include: (1) a valid prescription for Leqvio, (2) commercial insurance that covers Leqvio on any tier, and (3) enrollment through the Novartis program portal or via the prescriber's office. The savings card typically covers the difference between the plan's cost-sharing and $0, up to a maximum annual benefit amount set by Novartis.

Michigan patients whose commercial plan does not list Leqvio on its formulary at all will not benefit from the savings card; their insurer will deny the claim entirely. In that scenario, the patient's options are: (1) request a formulary exception, (2) appeal using ACC/AHA guideline language and the ORION-10/ORION-11 trial data as clinical support, [2] (3) transition to a compounded inclisiran formulation via 503A pharmacy, or (4) explore the Novartis Patient Assistance Program (PAP) for uninsured or underinsured patients whose income falls below program thresholds.

Which Michigan Insurance Plans Cover Leqvio?

Coverage varies by plan and plan year, so patients must verify the current formulary directly with their insurer. As a general reference:

Blue Cross Blue Shield of Michigan typically covers Leqvio under its specialty tier with PA for commercially insured members. The Medicare Advantage plans offered by BCBS Michigan follow CMS formulary requirements and may place Leqvio on a non-preferred specialty tier.

Priority Health (Michigan) covers PCSK9-targeting therapies including inclisiran on its specialty formulary with PA and step-therapy requirements, usually requiring a statin and ezetimibe failure documented in the medical record. [14]

Aetna, UnitedHealthcare, and Cigna Michigan commercial plans generally cover Leqvio on specialty tiers with PA. Each plan's 2026 formulary should be confirmed via the plan's drug lookup tool or by calling the member services number on the insurance card.

Michigan Medicare Part D stand-alone plans are required under CMS rules to cover drugs in the PCSK9 inhibitor class, though plan-level tier placement differs. The 2025-and-beyond $2,000 annual out-of-pocket cap under the Inflation Reduction Act means that even without a savings card, Medicare Part D patients' total annual exposure for Leqvio is capped. [8]

Medicaid managed care plans in Michigan follow the MDHHS PDL as a baseline. All plans must cover PDL drugs with the same PA criteria or less restrictive criteria; no plan can impose stricter requirements than the state PDL. [9]

LDL-C Targets and When Inclisiran Becomes the Right Choice in Michigan

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease sets an LDL-C goal of <70 mg/dL for very-high-risk ASCVD patients. [15] For patients already on high-intensity statins and ezetimibe who cannot reach that goal, PCSK9-targeting therapies provide the next level of LDL-C reduction.

Inclisiran's twice-yearly dosing schedule is its main practical advantage over alirocumab (Praluent) and evolocumab (Repatha), which require every-two-weeks or monthly self-injection. Adherence data from real-world PCSK9 monoclonal antibody use show that approximately 50% of patients discontinue within 12 months, [16] in part due to injection fatigue. Inclisiran's six-month interval addresses this problem directly.

A Michigan patient on atorvastatin 40 mg plus ezetimibe 10 mg with an LDL-C of 85 mg/dL is a straightforward candidate. After two loading injections (day 1 and day 90) and the first maintenance injection at month 6, ORION-10 data predict approximately 50% LDL-C reduction, bringing that patient to roughly 42 mg/dL, well below guideline targets. [2]

Inclisiran does not require refrigeration at the point of care during administration and has a shelf life allowing standard specialty pharmacy shipping to Michigan clinics, including practices in the Upper Peninsula where specialty pharmacy logistics can be a barrier for other biologics.

Safety Profile: What Michigan Patients Should Know Before Starting

Inclisiran's safety profile in the ORION-10 and ORION-11 trials (combined N=3,178) showed no statistically significant difference from placebo in rates of serious adverse events, liver function test abnormalities, or muscle-related adverse events. [2] The most common adverse effect was injection-site reaction, occurring in 2.6% of inclisiran versus 0.9% placebo recipients in ORION-10. [2]

The FDA label notes no required dose adjustment for mild to moderate renal impairment. [1] Patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) were not included in the key trials; prescribers should use clinical judgment in this population. No hepatic dose adjustment is recommended for mild to moderate hepatic impairment; the drug has not been studied in severe hepatic impairment.

Drug interactions are minimal given inclisiran's siRNA mechanism; it does not inhibit or induce CYP450 enzymes. [1] This is a practical advantage for Michigan patients with polypharmacy, a common situation in the ASCVD population where statins, antihypertensives, anticoagulants, and antidiabetics are frequently combined.

The American College of Cardiology notes that PCSK9-targeting therapies, including inclisiran, appear safe in pregnancy based on animal data, but human data are insufficient; patients of reproductive potential should use contraception and discontinue inclisiran before a planned pregnancy. [5]

How to Get Inclisiran in Michigan: Step-by-Step

Getting inclisiran in Michigan requires a few coordinated steps, none of which are prohibitively complex with the right clinical team.

Step 1. Obtain a recent (within 90 days) fasting lipid panel showing LDL-C and a cardiovascular risk assessment confirming ASCVD or HeFH diagnosis.

Step 2. Consult with a Michigan-licensed physician or APP, either in-person or via telehealth. The clinician confirms that maximally tolerated statin therapy with or without ezetimibe has been tried and LDL-C remains above target.

Step 3. The prescriber submits a PA request to the patient's insurer (if applicable) with supporting documentation including lipid values, current medications, and the ASCVD/HeFH diagnosis code.

Step 4. On PA approval, the prescription is sent to the patient's specialty pharmacy or a 503A compounding pharmacy. For brand Leqvio, the Novartis savings card enrollment happens at this step for commercially insured patients.

Step 5. The first injection (284 mg subcutaneous) is administered at a clinic. The second loading dose follows at day 90. Maintenance injections occur every six months thereafter.

The entire process from first telehealth visit to first injection can take as little as 10 to 14 days when documentation is complete and the insurer processes PA within standard timelines. Denials add 15 to 30 days for appeal.

Cost Comparison: Brand Leqvio vs. Compounded Inclisiran vs. PCSK9 Monoclonal Antibodies in Michigan

| Therapy | Michigan 2026 List Price | Dosing Frequency | Michigan Medicaid Coverage | |---|---|---|---| | Leqvio (inclisiran) | ~$3,250/injection (~$540/month) | Twice yearly | Yes, with PA | | Evolocumab (Repatha) | ~$650/month | Every 2 weeks or monthly | Yes, with PA | | Alirocumab (Praluent) | ~$540/month | Every 2 weeks or monthly | Yes, with PA | | Compounded inclisiran (503A) | Significantly below WAC | Twice yearly | Not covered |

Evolocumab and alirocumab are monoclonal antibodies with a longer track record in real-world use and extensive outcomes data including the FOURIER trial (N=27,564, evolocumab reduced major cardiovascular events by 15% vs. placebo at a median 2.2 years, P<0.001) [17] and the ODYSSEY OUTCOMES trial (N=18,924, alirocumab reduced major adverse cardiovascular events by 15% vs. placebo, P<0.001). [18] Inclisiran's ORION-4 trial (N=15,000, ongoing) is collecting hard cardiovascular endpoints; surrogate LDL-C data are strong but comparative outcomes data with monoclonal antibodies are not yet available from a single head-to-head trial.

For a Michigan patient whose priority is dosing convenience and who is commercially insured with savings card access, inclisiran at $0 copay twice per year may be preferable to a biweekly self-injection regimen. For a Michigan Medicare patient without a savings card, monthly evolocumab or alirocumab may produce a lower Part D cost-sharing total depending on plan tier placement.

Frequently Asked Questions